1. Rutgers New Jersey Medical School
http://njms.rutgers.edu/research/cetr/index.cfm[11/28/2015 6:04:36 PM]
Overview
An epidemic of multidrug-resistant (MDR) bacetrial infections plagues global and U.S. healthcare, and with few new
antibiotics making it to market from a diminished pipeline, there is an unmet medical need for new therapeutics to treat
drug-resistant infections. Furthermore, effective therapies are urgently needed to address ongoing public health and
biosecurity concerns that high-threat select agent bacetria can be engineered to become resistant to currently available
antibiotics. The goal of the Rutgers CETR is to help develop a new generation of antibiotics against known MDR
bacetria. The CETR is a collaborative public-private partnership involving senior investigators at Rutgers University,
Rockefeller University and Cubist Pharmaceuticals. It will serve to jump-start the discovery of novel antibiotics by
joining together highly creative senior researchers and providing critical core resources to turn highly promising early
concept molecules into potential therapeutics suitable for clinical evaluation. The CETR will examine well established
and novel therapeutic targets, and it will facilitate target validation, chemical lead identification, structure-activity
relationship analysis, pharmacokinetics and therapeutic efficacy in animal models. The goal is to develop optimized
chemical lead compounds that are suitable antibiotic candidates for preclinical evaluation. Critical factors for success
include the strength of highly accomplished project and core leaders, a comprehensive and highly integrated
infrastructure of support cores for lead compound optimization and validation, and access to the Rutgers Regional
Biocontainment Laboratory (RBL), an NIH designated national research center for high-threat agents. Finally, the
CETR leadership group is highly experienced in executing product-oriented translational research and a Scientific
Advisory Committee comprised of veteran members of PhRMA and academia will guide them.
Projects
Project 1: Therapeutics for drug resistant-bacetria: Arylpropionyl-phloroglucinods

2. Rutgers New Jersey Medical School
http://njms.rutgers.edu/research/cetr/index.cfm[11/28/2015 6:04:36 PM]
PI: Richard Ebright, Rutgers, the State University of NJ
Project 2: Broad spectrum Tricyclics GyrB, ParE inhibitors for antibacetrial application
PI: Aileen Rubio, Cubist Pharmaceuticals
Project 3: Process and pathway based discovery of novel anti-TB drugs
PI: David Alland, Rutgers, the State University of NJ
Project 4: Synthetic environmental-peptide libraries as a source of novel antibiotics
PI: Sean Brady, Rockefeller University
Project 5: Bayesian models to accelerate antibacetrial drug discovery
PI: Joel Freundlich, Rutgers, the State University of NJ
Cores
Core A: Administrative
PI: David Perlin, Rutgers, the State University of NJ
Core B: In vivo and in vitro pharmacokinetics
PI: Veronique Dartois, Rutgers, the State University of NJ
Core C: Animal Model
PI: David Perlin, Rutgers, the State University of NJ
Core D: Medicinal Chemistry
PI: Joel Freundlich, Rutgers, the State University of NJ
Core E: Structural refinement
PI: Min Lu, Rutgers, the State University of NJ
Core F: In vitro screening
PI: Nancy Connell, Rutgers, the State University of NJ